Form 4: abrdn Life Sciences Investors Director Buys Shares
Insider Transaction (Form 4)
Chris Lavictoire Mahai, a Director of abrdn Life Sciences Investors, purchased 527 shares of common stock on July 16, 2026 for $19.92 per share.
Summary
- Open-market purchase: acquired 527 Common Stock at $19.92 ($10,498) on July 16, 2026; holds 527 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $10,498, committing personal capital to the stock.
Insider Transactions
Chris Lavictoire Mahai — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-16 | Open-market purchase | Common Stock | 527 | $20 | $10.5K | 527 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-16 | Open-market purchase (527 shares) |
Keywords
insider transaction, Form 4, HQL, abrdn Life Sciences Investors, bullish, Chris Lavictoire Mahai
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.